Switch theme
Sign up to access all valuation multiples
Kolon TissueGene Inc is a biopharmaceutical company that develops regenerative therapies for the treatment of various orthopedic disorders. It is developing four product candidates, TG-C, TG-B, TG-D and TG-N for regeneration of cartilage, bone, disc and nerve.
1999
n/a
LTM Revenue $3.6M
LTM EBITDA -$33.9M
$2.4B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Kolon TissueGene has a last 12-month revenue (LTM) of $3.6M and a last 12-month EBITDA of -$33.9M.
In the most recent fiscal year, Kolon TissueGene achieved revenue of $3.7M and an EBITDA of -$24.0M.
Kolon TissueGene expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Kolon TissueGene valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $3.6M | XXX | $3.7M | XXX | XXX | XXX |
| Gross Profit | $0.7M | XXX | $0.4M | XXX | XXX | XXX |
| Gross Margin | 20% | XXX | 12% | XXX | XXX | XXX |
| EBITDA | -$33.9M | XXX | -$24.0M | XXX | XXX | XXX |
| EBITDA Margin | -933% | XXX | -650% | XXX | XXX | XXX |
| EBIT | -$34.6M | XXX | -$16.0M | XXX | XXX | XXX |
| EBIT Margin | -953% | XXX | -434% | XXX | XXX | XXX |
| Net Profit | -$39.5M | XXX | -$24.6M | XXX | XXX | XXX |
| Net Margin | -1085% | XXX | -666% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $7.3M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Kolon TissueGene's stock price is KRW 40600 (or $30).
Kolon TissueGene has current market cap of KRW 3.31T (or $2.4B), and EV of KRW 3.32T (or $2.4B).
See Kolon TissueGene trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2.4B | $2.4B | XXX | XXX | XXX | XXX | $-1.11 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Kolon TissueGene has market cap of $2.4B and EV of $2.4B.
Kolon TissueGene's trades at 654.9x EV/Revenue multiple, and -100.7x EV/EBITDA.
Equity research analysts estimate Kolon TissueGene's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Kolon TissueGene has a P/E ratio of -60.9x.
See valuation multiples for Kolon TissueGene and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2.4B | XXX | $2.4B | XXX | XXX | XXX |
| EV (current) | $2.4B | XXX | $2.4B | XXX | XXX | XXX |
| EV/Revenue | 664.5x | XXX | 654.9x | XXX | XXX | XXX |
| EV/EBITDA | -71.2x | XXX | -100.7x | XXX | XXX | XXX |
| EV/EBIT | -69.7x | XXX | -151.0x | XXX | XXX | XXX |
| EV/Gross Profit | 3322.4x | XXX | n/a | XXX | XXX | XXX |
| P/E | -60.9x | XXX | -97.8x | XXX | XXX | XXX |
| EV/FCF | -38.3x | XXX | -34.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialKolon TissueGene's last 12 month revenue growth is 8%
Kolon TissueGene's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.
Kolon TissueGene's rule of 40 is -404% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Kolon TissueGene's rule of X is -912% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Kolon TissueGene and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 8% | XXX | 9% | XXX | XXX | XXX |
| EBITDA Margin | -933% | XXX | -650% | XXX | XXX | XXX |
| EBITDA Growth | 88% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -404% | XXX | -642% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -912% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 15% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 111% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 445% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Lineage Cell Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Arovella Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Aroa Biosurgery | XXX | XXX | XXX | XXX | XXX | XXX |
| Cynata Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Mesoblast | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Kolon TissueGene acquired XXX companies to date.
Last acquisition by Kolon TissueGene was XXXXXXXX, XXXXX XXXXX XXXXXX . Kolon TissueGene acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Kolon TissueGene founded? | Kolon TissueGene was founded in 1999. |
| Where is Kolon TissueGene headquartered? | Kolon TissueGene is headquartered in South Korea. |
| Is Kolon TissueGene publicy listed? | Yes, Kolon TissueGene is a public company listed on KRX. |
| What is the stock symbol of Kolon TissueGene? | Kolon TissueGene trades under 950160 ticker. |
| When did Kolon TissueGene go public? | Kolon TissueGene went public in 2017. |
| Who are competitors of Kolon TissueGene? | Similar companies to Kolon TissueGene include e.g. Lineage Cell Therapeutics, Arovella Therapeutics, Aroa Biosurgery, Cynata Therapeutics. |
| What is the current market cap of Kolon TissueGene? | Kolon TissueGene's current market cap is $2.4B |
| What is the current revenue of Kolon TissueGene? | Kolon TissueGene's last 12 months revenue is $3.6M. |
| What is the current revenue growth of Kolon TissueGene? | Kolon TissueGene revenue growth (NTM/LTM) is 8%. |
| What is the current EV/Revenue multiple of Kolon TissueGene? | Current revenue multiple of Kolon TissueGene is 664.5x. |
| Is Kolon TissueGene profitable? | Yes, Kolon TissueGene is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Kolon TissueGene? | Kolon TissueGene's last 12 months EBITDA is -$33.9M. |
| What is Kolon TissueGene's EBITDA margin? | Kolon TissueGene's last 12 months EBITDA margin is -933%. |
| What is the current EV/EBITDA multiple of Kolon TissueGene? | Current EBITDA multiple of Kolon TissueGene is -71.2x. |
| What is the current FCF of Kolon TissueGene? | Kolon TissueGene's last 12 months FCF is -$63.0M. |
| What is Kolon TissueGene's FCF margin? | Kolon TissueGene's last 12 months FCF margin is -1735%. |
| What is the current EV/FCF multiple of Kolon TissueGene? | Current FCF multiple of Kolon TissueGene is -38.3x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
